ADVM
Income statement / Annual
Last year (2024), Adverum Biotechnologies, Inc.'s total revenue was $1.00 M,
a decrease of 72.22% from the previous year.
In 2024, Adverum Biotechnologies, Inc.'s net income was -$130.93 M.
See Adverum Biotechnologies, Inc.,s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2024
|
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
FY-2015
|
| Period Ended |
12/31/2024 |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
12/31/2017 |
12/31/2016 |
12/31/2015 |
| Operating Revenue |
$1.00 M |
$3.60 M |
$0.00 |
$7.50 M |
$0.00 |
$250,000.00 |
$1.61 M |
$1.85 M |
$1.46 M |
$2.32 M |
| Cost of Revenue |
$3.65 M
|
$5.64 M
|
$6.53 M
|
$4.65 M
|
$4.16 M
|
$0.00
|
$0.00
|
$2.10 M
|
$0.00
|
$0.00
|
| Gross Profit |
-$2.65 M
|
-$2.04 M
|
-$6.53 M
|
$2.86 M
|
-$4.16 M
|
$250,000.00
|
$1.61 M
|
-$247,000.00
|
$1.46 M
|
$2.32 M
|
| Gross Profit Ratio |
-2.65
|
-0.57
|
0
|
0.38
|
0
|
1
|
1
|
-0.13
|
1
|
1
|
| Research and Development Expenses |
$77.04 M
|
$77.48 M
|
$99.28 M
|
$89.18 M
|
$73.31 M
|
$40.42 M
|
$50.13 M
|
$39.84 M
|
$31.67 M
|
$25.46 M
|
| General & Administrative Expenses |
$63.12 M
|
$49.92 M
|
$57.86 M
|
$64.44 M
|
$44.64 M
|
$28.38 M
|
$24.56 M
|
$20.86 M
|
$24.36 M
|
$22.11 M
|
| Selling & Marketing Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General & Administrative Expenses |
$63.12 M
|
$49.92 M
|
$57.86 M
|
$64.44 M
|
$44.64 M
|
$28.38 M
|
$24.56 M
|
$20.86 M
|
$24.36 M
|
$22.11 M
|
| Other Expenses |
$0.00
|
$0.00
|
$2.67 M
|
$582,000.00
|
$1.56 M
|
$4.06 M
|
$4.20 M
|
$2.70 M
|
$762,000.00
|
$370,000.00
|
| Operating Expenses |
$140.16 M
|
$127.59 M
|
$157.14 M
|
$153.62 M
|
$117.95 M
|
$68.80 M
|
$74.69 M
|
$60.70 M
|
$56.03 M
|
$47.57 M
|
| Cost And Expenses |
$140.16 M
|
$132.54 M
|
$157.14 M
|
$153.62 M
|
$117.95 M
|
$68.80 M
|
$74.69 M
|
$60.70 M
|
$56.03 M
|
$47.57 M
|
| Interest Income |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Interest Expense |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Depreciation & Amortization |
$3.65 M
|
$5.64 M
|
$6.53 M
|
$4.65 M
|
$4.16 M
|
$1.57 M
|
$1.75 M
|
$2.10 M
|
$1.60 M
|
$812,000.00
|
| EBITDA |
-$127.27 M |
-$123.30 M |
-$147.93 M |
-$140.90 M |
-$112.24 M |
-$62.91 M |
-$72.13 M |
-$54.05 M |
-$52.97 M |
-$46.74 M |
| EBITDA Ratio |
-127.27
|
-34.25
|
0
|
-18.79
|
0
|
-251.65
|
-44.74
|
-29.23
|
-36.4
|
-20.16
|
| Operating Income Ratio |
-139.16
|
-35.82
|
0
|
-19.48
|
0
|
-274.18
|
-48.44
|
-31.83
|
-79.23
|
-20.62
|
| Total Other Income/Expenses Net |
$8.23 M
|
$5.75 M
|
$549,000.00
|
-$481,000.00
|
$1.56 M
|
$4.06 M
|
-$796,000.00
|
$2.70 M
|
-$62.13 M
|
-$2.10 M
|
| Income Before Tax |
-$130.93 M
|
-$123.19 M
|
-$154.46 M
|
-$145.54 M
|
-$116.39 M
|
-$64.49 M
|
-$73.88 M
|
-$56.15 M
|
-$114.52 M
|
-$47.45 M
|
| Income Before Tax Ratio |
-130.93
|
-34.22
|
0
|
-19.41
|
0
|
-257.94
|
-45.83
|
-30.37
|
-78.71
|
-20.46
|
| Income Tax Expense |
$0.00
|
-$1.08 M
|
$74,000.00
|
$4.41 M
|
$1.11 M
|
$1.40 M
|
-$1.25 M
|
$0.00
|
-$775,000.00
|
$1.76 M
|
| Net Income |
-$130.93 M
|
-$117.17 M
|
-$154.54 M
|
-$145.54 M
|
-$117.51 M
|
-$64.49 M
|
-$72.63 M
|
-$56.15 M
|
-$113.75 M
|
-$47.45 M
|
| Net Income Ratio |
-130.93
|
-32.55
|
0
|
-19.41
|
0
|
-257.94
|
-45.05
|
-30.37
|
-78.18
|
-20.46
|
| EPS |
-6.62 |
-12.11 |
-15.57 |
-14.85 |
-13.8 |
-10.06 |
-1.18 |
-1.29 |
-3.14 |
-1.86 |
| EPS Diluted |
-6.62 |
-12.11 |
-15.57 |
-14.85 |
-13.8 |
-10.06 |
-1.18 |
-1.29 |
-3.14 |
-1.84 |
| Weighted Average Shares Out |
$19.78 M
|
$10.08 M
|
$9.93 M
|
$9.80 M
|
$8.51 M
|
$6.41 M
|
$61.38 M
|
$43.66 M
|
$36.25 M
|
$25.48 M
|
| Weighted Average Shares Out Diluted |
$19.78 M
|
$10.08 M
|
$9.93 M
|
$9.80 M
|
$8.51 M
|
$6.41 M
|
$61.38 M
|
$43.66 M
|
$36.25 M
|
$25.86 M
|
| Link |
|
|
|
|
|
|
|
|
|
|
